NVTA

SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch. Founded by Farid Vij (CEO & Co-founder), Nasha Fitter (Chief Business Officer & Co-founder), and a team of industry veterans, Citizen Health is pioneering a new paradigm in healthcare by empowering patients—especially those with

Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%. The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign currency translation of 0.5%.  The 2.3% increase in organic revenue was driven by a 4.2% increase in the company’s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing).  The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago. Diagnostics Laboratories revenue for the quarter was $2.48 billion, an increase of 4.1%. Total volume

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a novel machine learning approach designed to aid clinical interpretation of genetic testing results and increase the rate of definitive answers for patients. The first of its kind, developed by a multidisciplinary team of computational biologists, machine learning engineers, clinical experts and geneticists, Clinical Variant Modeling methodically leverages clinical information received at the time of tes

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> Estimated unaudited financial results for fourth quarter 2023 Fourth quarter 2023 revenue was $127.8 mil

– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC:NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mis

25-NSE - Invitae Corp (0001501134) (Subject)

8-K - Invitae Corp (0001501134) (Filer)

 – Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO, Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders. 

SC 13G/A - Invitae Corp (0001501134) (Subject)

SC 13G/A - Invitae Corp (0001501134) (Subject)

SoftBank Group Corp (OTC:SFTBY) (OTC:SFTBF) backed Cohesity has agreed to the acquisition of the data protection business of Veritas Technologies LLC. The deal is valued at $3 billion, creating a combined entity worth $7 billion. What Happened: Cohesity, a U.S.-based data security software company, is set to acquire the data protection business of Veritas, a subsidiary of Carlyle Group Inc (NASDAQ:CG). The deal, comprising cash and stock, is expected to be finalized by the end of the year, as per source-based report by Reuters. The acquisition is anticipated to bolster Cohesity’s growth margins and facilitate its expansion into international markets. The combined annual revenue of the

U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.25% to 38,618.79 while the NASDAQ rose 0.34% to 15,661.70. The S&P 500 also rose, gaining, 0.34% to 4,971.18. Check This Out: Top 5 Energy Stocks That May Explode In February   Leading and Lagging Sectors   Consumer discretionary shares rose by 0.7% on Wednesday. In trading on Wednesday, utilities shares fell by 0.2%.   Top Headline   Uber Technologies, Inc (NYSE:UBER) reported better-than-expected fourth-quarter sales. Uber reported fourth-quarter FY23 revenue growth of 15% year-on-year to $9.94 billion, beating the cons

8-K - Invitae Corp (0001501134) (Filer)

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options, and bankruptcy is a prominent consideration.  The company, known for its aggressive acquisition approach in recent years, has initiated the shedding of assets and cost-cutting measures to add

Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) stock increased by 75.2% to $30.64 during Monday's regular session. The company's market cap stands at $1.3 billion. Yield10 Bioscience (NASDAQ:YTEN) stock rose 61.76% to $0.37. The market value of their outstanding shares is at $4.4 million. MorphoSys (NASDAQ:MOR) stock moved upwards by 50.76% to $16.69. The market value of their outstanding shares is at $2.5 billion. Karyopharm Therapeutics (NASDAQ:KPTI) shares moved upwards by 31.73% to $1.37. The company's market cap stands at $156.9 million. Adverum Biotechnologies (NASDAQ:ADVM) stock moved upwards by 28.86% to $1.83. The company's market cap stands at $184.8 million. Mira Pharmaceut

https://www.wsj.com/articles/softbank-backed-medical-genetics-company-invitae-prepares-for-bankruptcy-d468f120?st=02yzwzf1bnabmx0&mod=googlenewsfeed Invitae, a medical genetics company that received backing from SoftBank Group at the height of the pandemic has hired restructuring advisers and is preparing to file for bankruptcy within weeks, according to people familiar with the matter. The company is working with FTI Consulting and law firm Kirkland & Ellis to explore strategic options, including bankruptcy, to address $1.5 billion in debt on its balance sheet, the people said.   

SC 13G/A - Invitae Corp (0001501134) (Subject)

 Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. 

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.  www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic info